New hope for myeloma patients as combo therapy enters safety trials
NCT ID NCT05050097
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 32 times
Summary
This early-stage study tests the safety and best dose of talquetamab when combined with other cancer drugs for people with multiple myeloma, a type of blood cancer. About 166 participants will receive different drug combinations to see how well they tolerate the treatment and what side effects occur. The goal is to find safe doses for future studies, not to cure the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alfred Health
Melbourne, 3004, Australia
-
CHU Nantes
Nantes, 44093, France
-
CHU de Bordeaux - Hospital Haut-Leveque
Pessac, 33604, France
-
Chu Rennes Hopital Pontchaillou
Rennes, 35000, France
-
Churchill Hospital
Oxford, OX3 7LE, United Kingdom
-
Cliniques Universitaires St-Luc
Brussels, 1200, Belgium
-
Colorado Blood Cancer Institute
Denver, Colorado, 80218, United States
-
Emory University
Atlanta, Georgia, 30322, United States
-
Gold Coast University Hospital
Southport, 4215, Australia
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Indiana University
Indianapolis, Indiana, 46202, United States
-
Institut Universitaire du cancer de Toulouse-Oncopole
Toulouse, 31059, France
-
Levine Cancer Institute
Charlotte, North Carolina, 28204, United States
-
Maastricht University Medical Centre
Maastricht, 6229 HX, Netherlands
-
Medical College Of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Mt. Sinai School of Medicine
New York, New York, 10029, United States
-
St Vincents Hospital Melbourne
Fitzroy, 3065, Australia
-
Tennessee Oncology
Nashville, Tennessee, 37203, United States
-
The Christie Nhs Foundation Trust
Manchester, M20 4BX, United Kingdom
-
The Royal Marsden NHS Trust Sutton
Surrey, SM2 5PT, United Kingdom
-
UMCG
Groningen, 9713 GZ, Netherlands
-
UMCU
Utrecht, 3584 CX, Netherlands
-
UZ Gent
Ghent, 9000, Belgium
-
UZ Leuven
Leuven, 3000, Belgium
-
UZA
Edegem, 2650, Belgium
-
University College Hospital London
London, W1T 7HA, United Kingdom
-
University of Alabama Birmingham
Birmingham, Alabama, 35294, United States
-
University of California San Francisco
San Francisco, California, 94143, United States
-
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15232, United States
-
Weill Cornell Medical College
New York, New York, 10065, United States
-
Wollongong Hospital
Wollongong, 2500, Australia
Conditions
Explore the condition pages connected to this study.